YB Urban Renewal Residential Development Ltd, formerly known as Cannassure Therapeutics Ltd, is an Israel-based urban renewal company. The Company is engaged mainly in urban renewal projects. In the urban renewal projects sector, the Company partakes in activities that aim to clear out areas of inner cities deemed to be neglected, unused and loosely maintained, in favor of new multifamily housing, business areas, as well as other developments improving the city landscape. The Firm aims to achieve economic, cultural and environmental renewal of the neglected inner city areas. The Company cooperates with a range of specialists in the field of urban renewal with knowledge and experience in urban planning and construction work.

Employees

Sector

Real Estate Development & Operations

More about the company

Market Cap	28.38M 9.47M 8.11M 7.56M 6.94M 13.04M 906M 13.3M 89.74M 34.98M 454M 35.56M 34.78M 1.5B	P/E 2024	-4.93x	P/E 2025	-9.22x
Enterprise Value	28.5M 9.51M 8.14M 7.6M 6.97M 13.1M 910M 13.35M 90.1M 35.12M 456M 35.7M 34.92M 1.51B	EV / Sales 2024	376x	EV / Sales 2025	-
Free-Float	54.18%	Yield 2024 *	-	Yield 2025	-

05-04	Y.B Urban Renewal - Residential Development Ltd Reports Earnings Results for the Full Year Ended December 31, 2025	CI
05-03	Y.B Urban Renewal - Residential Development Ltd Auditor Raises 'Going Concern' Doubt	CI
11-13	Y.B Urban Renewal - Residential Development Ltd announced that it expects to receive ILS 0.53001 million in funding	CI
10/09/25	Y.B Urban Renewal - Residential Development Ltd Reports Earnings Results for the Half Year Ended June 30, 2025	CI
01/09/24	Y.B Urban Renewal - Residential Development Ltd Reports Earnings Results for the Half Year Ended June 30, 2024	CI
11/07/24	Cannassure Therapeutics Ltd will Change its Name to Y.B URBAN RENEWAL - RESIDENTIAL DEVELOPMENT LTD	CI
28/03/24	Y.B Urban Renewal - Residential Development Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI
27/03/24	Y.B Urban Renewal - Residential Development Ltd Auditor Raises 'Going Concern' Doubt	CI
31/08/23	Cannassure Therapeutics Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	CI
27/03/23	Cannassure Therapeutics Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	CI
09/08/21	Cannassure Was Granted A Patent for an Oral Delivery Method of Cannabis and Cannabinoids Compositions by the Israel Patents Authority	CI

26/02/21	DanCann Pharma A/S : publishes Year-end report for 2020	AQ
18/01/21	Cannassure Therapeutics : DanCann Pharma's strategic partner, Cannassure Therapeutics Ltd., enter exclusive licensing agreement regarding topical medical cannabis products based on Lipidor's AKVANO® technology	AQ
18/01/21	Lipidor : and Cannassure enter exclusive licensing agreement regarding topical medical cannabis products based on Lipidor's AKVANO technology	AQ
15/12/20	DanCann Pharma A/S : enter exclusive agreement with Cannassure Therapeutics to be multinational distributor for Scandinavia (Denmark, Norway, Sweden, and Finland)	AQ
19/11/20	Lipidor : publishes interim report for Q3 2020	AQ

Manager	Title	Age	Since
Ada Bar Kama CEO	Chief Executive Officer	56	31/03/2022
Oren Attiya DFI	Director of Finance/CFO	45	-
Daniel Shapira AUD	Comptroller/Controller/Auditor	72	26/06/2019

Director	Title	Age	Since
Nir Peles CHM	Chairman	53	09/12/2021
Shimon Bar-Kama BRD	Director/Board Member	74	04/12/2018
Varda Kalal BRD	Director/Board Member	58	14/02/2022

Cannassure Therapeutics Ltd Stock TEL AVIV STOCK EXCHANGE

Stocks

CSURE

IL0001110134

Real Estate Development & Operations

Valuation: Cannassure Therapeutics Ltd

Latest news : Cannassure Therapeutics Ltd

Press Releases: Cannassure Therapeutics Ltd

Quotes and Performance

Managers and Directors: Cannassure Therapeutics Ltd

Other Real Estate Development & Operations

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CANNASSURE THERAPEUTICS LTD	-7.54%	-22.20%	-	-	9.53M
SUN HUNG KAI PROPERTIES LIMITED	+3.74%	+6.04%	+37.64%	+41.14%	44.42B
CHINA RESOURCES LAND LIMITED	+3.16%	+0.69%	+11.66%	+10.82%	31.07B
MITSUBISHI ESTATE CO., LTD.	+1.83%	-0.11%	+14.93%	+114.58%	27.43B
EMAAR PROPERTIES	+0.36%	-1.95%	-26.02%	+63.13%	26.52B
MITSUI FUDOSAN CO., LTD.	+2.97%	+2.65%	-8.11%	+49.87%	24.57B
ALPHA DHABI HOLDING	0.00%	0.00%	-35.59%	-62.23%	20.68B
CK ASSET HOLDINGS LIMITED	+1.31%	+0.30%	+25.84%	+9.55%	20.51B
CHINA OVERSEAS LAND & INVESTMENT LIMITED	+1.36%	+2.83%	-0.70%	-12.00%	19.49B
SUMITOMO REALTY & DEVELOPMENT CO., LTD.	+3.36%	-0.65%	+7.07%	+93.87%	19.08B
Average	+1.06%	-0.94%	+2.97%	+34.30%	25.97B
Weighted average by Cap.	+2.20%	-0.74%	+6.29%	+37.10%

	2024	2025
Net sales	76K 25.36K 21.71K 20.26K 18.59K 34.93K 2.43M 35.62K 240K 93.68K 1.22M 95.21K 93.14K 4.03M	-
Net income	-3.68M -1.23M -1.05M -980K -899K -1.69M -117M -1.72M -11.62M -4.53M -58.8M -4.6M -4.5M -195M	-3M -1M -856K -799K -733K -1.38M -95.65M -1.4M -9.47M -3.69M -47.94M -3.75M -3.67M -159M
Net Debt	980K 327K 280K 261K 240K 450K 31.29M 459K 3.1M 1.21M 15.68M 1.23M 1.2M 51.91M	115K 38.37K 32.85K 30.65K 28.13K 52.85K 3.67M 53.89K 364K 142K 1.84M 144K 141K 6.09M